FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Juvaris BioTherapeutics

Juvaris completes $25M close of series B


Adjuvant vaccines developer Juvaris BioTherapeutics has completed the first close of a Series B round. The Burlingame, CA-based company says it will use the capital to advance its technology platform and carry its lead adjuvant, JVRS-100, into midstage clinical development for seasonal and pandemic flu.

The financing of up to $25 million was funded by SV Life Sciences and Kleiner Perkins Caufield & Byers (KPCB). SV Life Sciences' managing partner Michael Ross will join Juvaris Board of Directors. "Mike's highly successful drug development experience at Genentech and track record of building strong biotech companies at SVLS will be of critical ongoing value to Juvaris," said CEO Grant Pickering.

- here's the Juvaris release

Related Articles:
Juvaris strikes collaboration deal on new vaccines
Vaccine market trends, 2009 predictions
Emerging Drug Developer: Juvaris BioTherapeutics

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Juvaris BioTherapeutics  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.